Skip to search formSkip to main contentSkip to account menu

AVE9633

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antibodies, Monoclonal, HumanizedMaytansine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract 3523: Preclinical characterization of MT114, a novel CD33/CD3-bispecific BiTE antibody for the treatment of acute myeloid leukemia (AML)
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL There has been little improvement of standard of… 
2007
2007
An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive…
AVE9633/huMy9-6-DM4 is an immunoconjugate composed of a humanized monoclonal IgG 1 antibody, huMy9-6, which specifically targets… 
2006
2006
Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML).
AVE9633 is an immunoconjugate created by conjugation of the cytotoxic maytansinoid, DM4, to the monoclonal IgG1 antibody, huMy9-6… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)